Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11551 - 11575 of 11857 in total
PF-04856884 or CVX-060 is a selective angiopoietin (Ang)-2 inhibitor. It is under investigation in clinical trial NCT01441414 (PF-04856884 (CVX-060) in Combination With Axitinib in Patients With Previously Treated Metastatic Renal Cell Carcinoma).
Investigational
Matched Description: … PF-04856884 or CVX-060 is a selective angiopoietin (Ang)-2 inhibitor. …
LS11(talaporfin sodium) is an agent consisting of chlorin e6, derived from chlorophyll, and L-aspartic acid with photosensitizing activity. After intratumoral activation by light emitting diodes, taporfin sodium forms an extended high energy conformational state that generates singlet oxygen, resulting in free radical-mediated cell death. It is used to treat many...
Investigational
Encenicline has been investigated for the treatment of Cognition, Schizophrenia, Alzheimer's Disease, Cardiac Repolarization, and Central Nervous System Diseases.
Investigational
Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its active metabolite enoltasosartan. It is used to treat patients with essential hypertension.
Experimental
Matched Description: … Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. …
CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics is investigating for the potential treatment of asthma and other conditions related to inflammation and fibrosis.
Investigational
Matched Description: … CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics …
Clobutinol is a cough suppressant that is withdrawn from the US and EU markets. Clobutinol may prolong the QT interval. In 2007, Clobutinol was determined to cause cardiac arrhythmia in some patients.
Withdrawn
Matched Description: … Clobutinol is a cough suppressant that is withdrawn from the US and EU markets. …
Molibresib is under investigation in clinical trial NCT01943851 (A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies).
Investigational
Matched Description: … Molibresib is under investigation in clinical trial NCT01943851 (A Dose Escalation Study to Investigate …
IMC-1C11 is an anti-angiogenesis agent. It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation. IMC-1C11 is used for treatment of patients with liver metastases from colorectal carcinoma.
Investigational
Matched Description: … It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction …
VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase-1 (VRT-043198). VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.
Investigational
Matched Description: … VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase …
GFT14 is a new class of medicaction for treatment of cardiometabolic disease. GFT14 aims to target mixed dyslipidemia of type IIb (high levels of triglycerides and LDL-C) as one of the major indications of cardiometabolic disease. GFT14 is destined to improve the condition of patients at risk from cardiovascular disease...
Investigational
Matched Description: … GFT14 is a new class of medicaction for treatment of cardiometabolic disease. ... GFT14 is destined to improve the condition of patients at risk from cardiovascular disease by a simultaneous …
CX-717 is an ampakine compound previously investigated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Alzheimer's disease.
Illicit
Investigational
YSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid arthritis and psoriasis. The molecule works by inhibiting TNF-alpha and IL-6 production in T-cells and macrophages, and by inhibiting T-cell proliferation and migration.
Investigational
Matched Description: … YSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid …
T487 is a small molecule chemokine receptor antagonist to correct or modify immune system responses. It binds selectively and potently to CXCR3. The formulation is administered orally and has anti-inflammatory effects in conditions such as rheumatoid arthritis, inflammatory bowel disease and psoriasis.
Investigational
Matched Description: … T487 is a small molecule chemokine receptor antagonist to correct or modify immune system responses. …
Delgocitinib is under investigation in clinical trial NCT03683719 (Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 Mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema).
Investigational
Matched Description: … Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 Mg/g Compared to Delgocitinib Cream Vehicle Over a
D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the Pseudomonas exotoxin, PE38-KDEL. D2C7-IT is under investigation in clinical trial NCT04160494 (D2C7-IT With Atezolizumab for Recurrent Gliomas).
Investigational
Matched Description: … D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a
RGX-501 is an adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional copy of the human low-density lipoprotein receptor (LDLR) gene to liver cells. It is being investigated for the treatment of homozygous familial hypercholesterolemia.
Investigational
Matched Description: … RGX-501 is an adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional …
Experimental
An amphetamine derivative that inhibits uptake of catecholamine neurotransmitters. It is a hallucinogen. It is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally. [PubChem]
Experimental
Illicit
Matched Description: … It is a hallucinogen. …
Tezosentan is an intravenous endothelin receptor A/B antagonist. Tezosentan was initially developed for vasodilation in patients with acute heart failure but studies have shown that it does not assist in the treatment of dyspnea or prevent cardiovascular events.
Investigational
Matched Description: … Tezosentan is an intravenous endothelin receptor A/B antagonist. …
5-imino-4-(3-trifluoromethyl-phenylazo)-5H-pyrazol-3-ylamine is a solid. This compound belongs to the benzene and substituted derivatives. These are aromatic compounds containing at least one benzene ring. This drug targets the protein methionine aminopeptidase.
Experimental
Matched Description: … 5-imino-4-(3-trifluoromethyl-phenylazo)-5H-pyrazol-3-ylamine is a solid. …
Melarsomine is a trypanocidal agent marketed by Merial under the trade name Immiticide. It is the only FDA-approved treatment for adult heartworm infection in dogs, however, is is not approved for use in dogs with late-stage infection.
Experimental
Vet approved
Matched Description: … Melarsomine is a trypanocidal agent marketed by Merial under the trade name Immiticide. …
Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, Leukemia, Lymphocytic, Chronic, and Lymphoma, Large B-Cell, Diffuse. It is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells.
Investigational
Matched Description: … It is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells. …
Osoresnontrine is under investigation in clinical trial NCT02281773 (A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.).
Investigational
Matched Description: … Osoresnontrine is under investigation in clinical trial NCT02281773 (A Study to Investigate the Efficacy …
Pf 04995274 is under investigation in clinical trial NCT01193062 (Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274).
Investigational
Matched Description: … Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A
SC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) that has been studied in cancer therapy , lower back pain , and inflammation , , , .
Experimental
Investigational
Matched Description: … SC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) [L2964] that has been …
Displaying drugs 11551 - 11575 of 11857 in total